Chemogenomics approaches for receptor deorphanization and extensions of the chemogenomics concept to phenotypic space.
暂无分享,去创建一个
John P. Overington | Julio E. Peironcely | H. V. van Vlijmen | A. Bender | D. Spring | G. V. van Westen | A. IJzerman | Olaf O van den Hoven | Eelke van der Horst | W. R. Galloway | Joerg K Wegner | J. Wegner | W. Galloway
[1] Wolfgang Guba,et al. Development of a virtual screening method for identification of "frequent hitters" in compound libraries. , 2002, Journal of medicinal chemistry.
[2] Shane Weaver,et al. The importance of the domain of applicability in QSAR modeling. , 2008, Journal of molecular graphics & modelling.
[3] Gavin Harper,et al. Assessment of chemical coverage of kinome space and its implications for kinase drug discovery. , 2008, Journal of medicinal chemistry.
[4] Igor V. Tetko,et al. Critical Assessment of QSAR Models of Environmental Toxicity against Tetrahymena pyriformis: Focusing on Applicability Domain and Overfitting by Variable Selection , 2008, J. Chem. Inf. Model..
[5] D. Gloriam,et al. Definition of the G protein-coupled receptor transmembrane bundle binding pocket and calculation of receptor similarities for drug design. , 2009, Journal of medicinal chemistry.
[6] Thomas Bäck,et al. Substructure Mining Using Elaborate Chemical Representation , 2006, J. Chem. Inf. Model..
[7] Andreas Bender,et al. A Discussion of Measures of Enrichment in Virtual Screening: Comparing the Information Content of Descriptors with Increasing Levels of Sophistication , 2005, J. Chem. Inf. Model..
[8] T. Lundstedt,et al. Development of proteo-chemometrics: a novel technology for the analysis of drug-receptor interactions. , 2001, Biochimica et biophysica acta.
[9] Jean-Philippe Vert,et al. Virtual screening of GPCRs: An in silico chemogenomics approach , 2008, BMC Bioinformatics.
[10] R. Solé,et al. The topology of drug-target interaction networks: implicit dependence on drug properties and target families. , 2009, Molecular bioSystems.
[11] Julio E. Peironcely,et al. Chemogenomics: Looking at biology through the lens of chemistry , 2009 .
[12] Andreas Bender,et al. How Similar Are Similarity Searching Methods? A Principal Component Analysis of Molecular Descriptor Space , 2009, J. Chem. Inf. Model..
[13] Andreas Bender,et al. Databases: Compound bioactivities go public , 2010 .
[14] Xin Wen,et al. BindingDB: a web-accessible database of experimentally determined protein–ligand binding affinities , 2006, Nucleic Acids Res..
[15] T. Klabunde. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands , 2007, British journal of pharmacology.
[16] Didier Rognan,et al. A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.
[17] William P. Janzen,et al. A Chemogenomic Analysis of the Human Proteome: Application to Enzyme Families , 2007, Journal of biomolecular screening.
[18] R. Solé,et al. Data completeness—the Achilles heel of drug-target networks , 2008, Nature Biotechnology.
[19] Oliver Ebenhöh,et al. Ground State Robustness as an Evolutionary Design Principle in Signaling Networks , 2009, PloS one.
[20] H Kubinyi,et al. Chance favors the prepared mind--from serendipity to rational drug design. , 1999, Journal of receptor and signal transduction research.
[21] P. Bork,et al. A side effect resource to capture phenotypic effects of drugs , 2010, Molecular systems biology.
[22] E. Jacoby,et al. Chemogenomic strategies to expand the bioactive chemical space. , 2009, Current medicinal chemistry.
[23] J. Kazius,et al. Derivation and validation of toxicophores for mutagenicity prediction. , 2005, Journal of medicinal chemistry.
[24] T. Lundstedt,et al. Proteochemometrics modeling of the interaction of amine G-protein coupled receptors with a diverse set of ligands. , 2002, Molecular pharmacology.
[25] A. Bender,et al. Cover Picture: Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off-Target Effects from Chemical Structure (ChemMedChem 6/2007) , 2007 .
[26] M. Murcko,et al. Chemogenomic approaches to drug discovery. , 2001, Current opinion in chemical biology.
[27] A. Bender,et al. In silico target fishing: Predicting biological targets from chemical structure , 2006 .
[28] K. Fidelis,et al. Interaction Model Based on Local Protein Substructures Generalizes to the Entire Structural Enzyme‐Ligand Space. , 2009 .
[29] Klaus-Robert Müller,et al. Machine learning models for lipophilicity and their domain of applicability. , 2007, Molecular pharmaceutics.
[30] R. Glen,et al. Molecular similarity: a key technique in molecular informatics. , 2004, Organic & biomolecular chemistry.
[31] John A. Tallarico,et al. Multi-parameter phenotypic profiling: using cellular effects to characterize small-molecule compounds , 2009, Nature Reviews Drug Discovery.
[32] G. V. Paolini,et al. Global mapping of pharmacological space , 2006, Nature Biotechnology.
[33] Michael T. M. Emmerich,et al. A novel chemogenomics analysis of G protein-coupled receptors (GPCRs) and their ligands: a potential strategy for receptor de-orphanization , 2010, BMC Bioinformatics.
[34] John A. Tallarico,et al. Integrating high-content screening and ligand-target prediction to identify mechanism of action. , 2008, Nature chemical biology.
[35] Joseph Lehar,et al. Therapeutic selectivity and the multi-node drug target. , 2009, Discovery medicine.
[36] Michael T. M. Emmerich,et al. Chemogenomics: Looking at biology through the lens of chemistry , 2009, Stat. Anal. Data Min..
[37] Richard Morphy,et al. Designed Multiple Ligands. An Emerging Drug Discovery Paradigm , 2006 .
[38] A. Fliri,et al. Analysis of drug-induced effect patterns to link structure and side effects of medicines , 2005, Nature chemical biology.
[39] Adriaan P. IJzerman,et al. Substructure Mining of GPCR Ligands Reveals Activity-Class Specific Functional Groups in an Unbiased Manner , 2009, J. Chem. Inf. Model..
[40] E. Maréchal. Chemogenomics: a discipline at the crossroad of high throughput technologies, biomarker research, combinatorial chemistry, genomics, cheminformatics, bioinformatics and artificial intelligence. , 2008, Combinatorial chemistry & high throughput screening.
[41] Anthony J Williams,et al. Public chemical compound databases. , 2008, Current opinion in drug discovery & development.
[42] Andreas Bender,et al. Computational methods to support high-content screening: from compound selection and data analysis to postulating target hypotheses , 2009, Expert opinion on drug discovery.
[43] Andreas Bender,et al. Diversity-Oriented Synthesis: A Spectrum of Approaches and Results , 2008 .
[44] B. Stockwell. Chemical genetics: ligand-based discovery of gene function , 2000, Nature Reviews Genetics.
[45] J. Lehár,et al. Synergistic drug combinations improve therapeutic selectivity , 2009, Nature Biotechnology.
[46] P. Clemons,et al. Chemogenomic data analysis: prediction of small-molecule targets and the advent of biological fingerprint. , 2007, Combinatorial chemistry & high throughput screening.
[47] Nathanael Weill,et al. Development and Validation of a Novel Protein-Ligand Fingerprint To Mine Chemogenomic Space: Application to G Protein-Coupled Receptors and Their Ligands , 2009, J. Chem. Inf. Model..
[48] D. Spring. Chemical Genetics to Chemical Genomics: Small Molecules Offer Big Insights , 2005 .
[49] D. Rognan. Chemogenomic approaches to rational drug design , 2007, British journal of pharmacology.
[50] Bryan L Roth,et al. Screening the receptorome to discover the molecular targets for plant-derived psychoactive compounds: a novel approach for CNS drug discovery. , 2004, Pharmacology & therapeutics.
[51] Corey Nislow,et al. Combination chemical genetics. , 2008, Nature chemical biology.
[52] Bernhard Kuster,et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors , 2007, Nature Biotechnology.
[53] H. Kitano. A robustness-based approach to systems-oriented drug design , 2007, Nature Reviews Drug Discovery.
[54] David M. Rocke,et al. Predicting ligand binding to proteins by affinity fingerprinting. , 1995, Chemistry & biology.
[55] Andreas Bender,et al. Understanding False Positives in Reporter Gene Assays: in Silico Chemogenomics Approaches To Prioritize Cell-Based HTS Data , 2007, J. Chem. Inf. Model..
[56] C. Sander,et al. Models from experiments: combinatorial drug perturbations of cancer cells , 2008, Molecular systems biology.
[57] M. Vieth,et al. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. , 2004, Biochimica et biophysica acta.
[58] J. Mestres,et al. A ligand-based approach to mining the chemogenomic space of drugs. , 2008, Combinatorial chemistry & high throughput screening.
[59] U. Lessel,et al. In vitro and in silico affinity fingerprints: Finding similarities beyond structural classes , 2000 .
[60] E. Jacoby,et al. Chemogenomics: an emerging strategy for rapid target and drug discovery , 2004, Nature Reviews Genetics.
[61] Jordi Mestres,et al. Computational chemogenomics approaches to systematic knowledge-based drug discovery. , 2004, Current opinion in drug discovery & development.
[62] Xiaohua Ma,et al. Mechanisms of drug combinations: interaction and network perspectives , 2009, Nature Reviews Drug Discovery.
[63] Jean-Loup Faulon,et al. Genome scale enzyme–metabolite and drug–target interaction predictions using the signature molecular descriptor , 2008 .
[64] Pierre Acklin,et al. Similarity Metrics for Ligands Reflecting the Similarity of the Target Proteins , 2003, J. Chem. Inf. Comput. Sci..
[65] David A. Gough,et al. Virtual Screen for Ligands of Orphan G Protein-Coupled Receptors , 2005, J. Chem. Inf. Model..
[66] Horvath Dragos,et al. Predicting the predictability: a unified approach to the applicability domain problem of QSAR models. , 2009, Journal of chemical information and modeling.
[67] Gerard J. P. van Westen,et al. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets , 2011 .
[68] Z. Deng,et al. Bridging chemical and biological space: "target fishing" using 2D and 3D molecular descriptors. , 2006, Journal of medicinal chemistry.
[69] A. Bender,et al. Assessment of structural diversity in combinatorial synthesis. , 2005, Current opinion in chemical biology.
[70] David Rogers,et al. Extended-Connectivity Fingerprints , 2010, J. Chem. Inf. Model..
[71] Péter Csermely,et al. The efficiency of multi-target drugs: the network approach might help drug design. , 2004, Trends in pharmacological sciences.
[72] P. Bork,et al. Drug Target Identification Using Side-Effect Similarity , 2008, Science.
[73] David S. Wishart,et al. DrugBank: a comprehensive resource for in silico drug discovery and exploration , 2005, Nucleic Acids Res..
[74] E. Jacoby. A Novel Chemogenomics Knowledge-Based Ligand Design Strategy—Application to G Protein-Coupled Receptors , 2001 .
[75] Mindy I. Davis,et al. A quantitative analysis of kinase inhibitor selectivity , 2008, Nature Biotechnology.
[76] Michael J. Keiser,et al. Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.
[77] A. Bender,et al. Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.
[78] Andreas Bender,et al. "Bayes Affinity Fingerprints" Improve Retrieval Rates in Virtual Screening and Define Orthogonal Bioactivity Space: When Are Multitarget Drugs a Feasible Concept? , 2006, J. Chem. Inf. Model..